Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What AJANTPHARM guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 30 Oct 2026 | Board approved unaudited consolidated and standalone financial results for Q2 and half year ended 30 September 2026 (board meeting held 30 October 2026, 11:30 a.m. to 12:50 p.m.). Q2 FY2027 consolidated revenue from operations Rs 1,794 cr vs Rs 1,354 cr (up 33%); adjusted EBITDA (excluding forex loss) Rs 543 cr vs... NSE copy | No results filed since | ||
Filings tagged as guidance, newest first (1 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.